Nesivine Sine Conservans (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nesivine Sine Conservans, is a alpha‑adrenergic agonist presented as a nasal decongestant for nasal use. It relieves congestion associated with the common cold, sinusitis and allergic rhinitis in adults and children.

GNH USA supplies Nesivine Sine Conservans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline Hydrochloride acts on nasal blood vessels to reduce swelling and improve airflow in several upper‑respiratory conditions. - Common cold nasal congestion: reduces swelling of nasal mucosa to improve breathing. - Sinusitis‑related congestion: alleviates blockage of sinus passages. - Allergic rhinitis: diminishes nasal swelling caused by allergen exposure.

Nesivine Sine Conservans may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Mild headache - Altered taste sensation - Transient nasal bleeding

Serious or Rare Side Effects: - Rebound congestion (rhinitis medicamentosa) with prolonged use - Elevated blood pressure or hypertension - Tachycardia or arrhythmia - Severe allergic reaction (anaphylaxis) - Nasal ulceration or perforation - Vision changes due to orbital pressure

Before using Nesivine Sine Conservans, consider the following safety measures. - Use in children under 6 years: not recommended unless directed by a physician. - Pregnancy: safety not established; consult a healthcare provider. - Concurrent MAO inhibitor therapy: avoid due to risk of hypertensive events. - Patients with hypertension or cardiovascular disease: monitor blood pressure closely. - Avoid prolonged use beyond three days: risk of rebound congestion. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline may interact with other medications; review the following categories.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Sympathomimetic agents (e.g., pseudoephedrine): additive vasoconstriction. - Other nasal decongestants: increased risk of severe vasoconstriction.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may mask tachycardia. - Antihypertensive drugs: possible reduction in blood‑pressure‑lowering effect. - Tricyclic antidepressants: potential for additive cardiovascular effects.